Please assess the completion status of the following clinical trial:

Trial Title: Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* the diagnosis of systemic lupus erythematosus (by meeting 4 criteria of the American College of Rheumatology)~* renal biopsy documenting lupus nephritis according to the classification of the World Health Organization (WHO) or the updated International Society of Nephrology/Renal Pathology Society (ISN/RPS) as proliferative glomerulonephritis class III (focal) or IV (diffuse)~* clinical activity as defined by presence of at least two of the following:~  * abnormal proteinuria (more than 500mg of protein in in a 24-hour urine specimen)~ * abnormal microscopic hematuria, or~ * C3 hypocomplementemia (the latter two were defined according to the norms in the laboratories of the participating centers)~Exclusion Criteria:~* treatment with cyclophosphamide or cyclosporine A ever before~* treatment with other immunosuppressive drugs (such as azathioprine or mycophenolate mofetil) or high dose glucocorticoids (≥ 80mg of prednisone or methylprednisolone) within the last 3 months~* persistent elevation of serum creatinine (≥140 μmol/l)~* pregnancy or lactation~* bone marrow insufficiency with cytopenias not attributable to SLE, and 8severe coexisting conditions, such as infection, liver disease, active peptic ulcer etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cyclosporine A (Type: EXPERIMENTAL): Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months.
- Cyclophosphamide (Type: ACTIVE_COMPARATOR): Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals).

Based on this trial design, predict the completion outcome and termination type (if applicable).